B230315N10Rik Activators
B230315N10Rik Activators encompass a diverse array of chemical compounds that enhance the functional activity of B230315N10Rik through various specific signaling pathways. Agents such as Forskolin and IBMX increase intracellular cAMP, leading to the activation of PKA, which may subsequently phosphorylate and activate B230315N10Rik. PMA, through the activation of PKC, and Ionomycin, by increasing intracellular calcium levels, potentially activate calcium-dependent protein kinases that could phosphorylate B230315N10Rik, enhancing its activity. Similarly, Epigallocatechin gallate, by inhibiting certain kinases, might remove inhibitory phosphorylations from B230315N10Rik, thus augmenting its function. The PI3K inhibitor LY294002 could disrupt normal AKT signaling, leading to compensatory cellular responses that enhance B230315N10Rik activity, while Okadaic acid's inhibition of protein phosphatases could increase B230315N10Rik phosphorylation and activation.
B230315N10Rik Activators are a collection of chemical entities that boost the functional activity of B230315N10Rik through distinct and specific intracellular signaling pathways. Forskolin and IBMX orchestrate an increase in the intracellular concentration of cAMP, which in turn activates PKA, and this kinase may target B230315N10Rik for phosphorylation, enhancing its activity. PMA, as a PKC activator, and Ionomycin, elevating intracellular calcium levels, could initiate a cascade of phosphorylation events through calcium-dependent protein kinases, potentially culminating in the activation of B230315N10Rik. Epigallocatechin gallate, which inhibits certain kinases, could alleviate inhibitory phosphorylations on B230315N10Rik, leading to its activation, while LY294002 disrupts PI3K/AKT signaling, possibly resulting in a compensatory cellular reconfiguration that activates B230315N10Rik. Additionally, the inhibition of protein phosphatases by Okadaic acid could lead to a net increase in the phosphorylated state of B230315N10Rik, thereby enhancing its activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, preventing the breakdown of cAMP and thereby increasing its levels. Elevated cAMP activates PKA, which could indirectly lead to the activation of B230315N10Rik through phosphorylation mechanisms. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC activation can result in the phosphorylation of downstream proteins, which may include B230315N10Rik, thus enhancing its functional activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, potentially activating calcium-dependent protein kinases. These kinases could phosphorylate and therefore enhance the activity of B230315N10Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate inhibits certain types of kinases, which could remove inhibitory phosphorylations on various proteins, including B230315N10Rik, thereby enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K, which can alter AKT signaling. The disruption of normal PI3K/AKT signaling pathways might enhance the activity of B230315N10Rik through compensatory mechanisms within the signaling network. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation levels of proteins. This could result in enhanced phosphorylation and activation of B230315N10Rik. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a JNK activator that can lead to the phosphorylation of c-Jun, which may influence gene expression patterns favoring the activation of B230315N10Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an MEK inhibitor, which could shift the balance of MAPK pathway signaling. This shift might indirectly enhance the activity of B230315N10Rik by modifying downstream effectors. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is an inhibitor of p38 MAPK, leading to an alteration in p38 pathway signaling. This change could result in an indirect increase in the activity of B230315N10Rik through downstream effects. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is a specific inhibitor of CaMKII (calcium/calmodulin-dependent protein kinase II). Inhibition of CaMKII can lead to a reconfiguration of calcium-dependent signaling, potentially enhancing the functional activity of B230315N10Rik. | ||||||